Synthesis and Stability of Actinium-225 Endohedral Fullerenes, 225Ac@C60 [PDF]
ACS Omega, 2020 We report the first synthesis of 225Ac (t 1/2 = 10 days) endohedral fullerenes,225Ac@C60. The 225Ac@C60 was produced with a 12 ± 2% efficiency by applying an electrical arc discharge between a source of α-particle emitter 225Ac (∼1 mCi, electroplated on a Pt disk) and a thin coat of "preformed" C60 on an Al disk (C60 thickness of ∼0.25 mg/cm2).
Jofa Gideon Mwakisege +2 more
doaj +5 more sources
The determination of the radiochemical purity of Actinium-225 radiopharmaceuticals: a conundrum [PDF]
EJNMMI Radiopharmacy and Chemistry, 2022 Janke Kleynhans, Adriano Duatti
doaj +4 more sources
Quantitative SPECT/CT imaging of actinium-225 for targeted alpha therapy of glioblastomas [PDF]
EJNMMI PhysicsBackground A new, alternative option for patients with recurrent glioblastoma is targeted alpha therapy (TAT), in the form of a local administration of substance P (neurokinin type 1 receptor ligand, NK-1) labelled with 225Ac.
Monika Tulik +8 more
doaj +2 more sources
Current and future targeted alpha particle therapies for osteosarcoma: Radium-223, actinium-225, and thorium-227 [PDF]
Frontiers in Medicine, 2022 Osteosarcoma is a high-grade sarcoma characterized by osteoid formation, nearly universal expression of IGF1R and with a subset expressing HER-2. These qualities provide opportunities for the use of the alpha particle-emitting isotopes to provide ...
Peter M. Anderson +3 more
doaj +2 more sources
A Proof-of-Concept Study on the Therapeutic Potential of Au Nanoparticles Radiolabeled with the Alpha-Emitter Actinium-225 [PDF]
Pharmaceutics, 2020 Actinium-225 (225Ac) is receiving increased attention for its application in targeted radionuclide therapy, due to the short range of its emitted alpha particles in conjunction with their high linear energy transfer, which lead to the eradication of ...
Evangelia-Alexandra Salvanou +11 more
doaj +2 more sources
Alpha Therapy Beyond TOC and TATE—Production, Quality Control, and In-Human Results for the SSTR2 Antagonist DOTA-LM3 [PDF]
PharmaceuticalsObjectives: Peptide receptor radionuclide therapy (PRRT) of neuroendocrine tumors (NETs) commonly relies on somatostatin receptor subtype 2 (SSTR2) agonists such as DOTA-TOC/TATE, which may show limited efficacy due to high hepatic uptake and therapy ...
Lukas Greifenstein +8 more
doaj +2 more sources
Towards DFO*12—Preliminary Results of a New Chelator for the Complexation of Actinium-225 [PDF]
PharmaceuticsBackground: Actinium-225 (225Ac) has gained interest in nuclear medicine for use in targeted alpha therapy (TAT) for the treatment of cancer. However, the number of suitable chelators for the stable complexation of 225Ac3+ is limited.
Irene V. J. Feiner +9 more
doaj +2 more sources
Exploratory case series of circulating tumor DNA dynamics during tandem therapy in metastatic castration-resistant prostate cancer [PDF]
EJNMMI ResearchBackground Prostate-specific membrane antigen (PSMA)-targeted radiopharmaceutical therapy (RPT) with the alpha-emitter actinium-225 (225Ac) has shown promising activity in metastatic castration-resistant prostate cancer (mCRPC), but its use is limited by
Mariam Amghar +9 more
doaj +2 more sources
Optimization of Cation Exchange for the Separation of Actinium-225 from Radioactive Thorium, Radium-223 and Other Metals [PDF]
Molecules, 2019 Actinium-225 (225Ac) can be produced with a linear accelerator by proton irradiation of a thorium (Th) target, but the Th also underdoes fission and produces 400 other radioisotopes.
Jonathan Fitzsimmons +6 more
doaj +2 more sources
Actinium-225 Targeted Agents: Where Are We Now? [PDF]
Brachytherapy, 2023 α-particle targeted radionuclide therapy has shown promise for optimal cancer management, an exciting new era for brachytherapy. Alpha-emitting nuclides can have significant advantages over gamma- and beta-emitters due to their high linear energy transfer (LET).
Mourtada F +8 more
europepmc +3 more sources